Zhang Ka, Liu Yuan, Mao Aiqin, Li Changzhu, Geng Li, Kan Hao
Wuxi School of Medicine Jiangnan University Wuxi Jiangsu China.
School of Food Science and Technology Jiangnan University Wuxi Jiangsu China.
J Am Heart Assoc. 2025 Feb 4;14(3):e038193. doi: 10.1161/JAHA.124.038193. Epub 2025 Feb 3.
The proteome is a key source of therapeutic targets. We conducted a comprehensive Mendelian randomization analysis across the proteome to identify potential protein markers and therapeutic targets for abdominal aortic aneurysm (AAA).
Our study used plasma proteomics data from the UK Biobank, comprising 2923 proteins from 54 219 individuals, and from deCODE Genetics, which measured 4907 proteins across 35 559 individuals. Significant proteomic quantitative trait loci were used as instruments for Mendelian randomization. Genetic associations with AAA were sourced from the AAAgen consortium, a large-scale genome-wide association study meta-analysis involving 37 214 cases and 1 086 107 controls, and the FinnGen study, which included 3869 cases and 381 977 controls. Sequential analyses of colocalization and summary-data-based Mendelian randomization were performed to verify the causal roles of candidate proteins. Additionally, single-cell expression analysis, protein-protein interaction network analysis, pathway enrichment analysis, and druggability assessments were conducted to identify cell types with enriched expression and prioritize potential therapeutic targets. The proteome-wide Mendelian randomization analysis identified 34 proteins associated with AAA risk. Among them, 2 proteins, COL6A3 and PRKD2, were highlighted by colocalization analysis, summary-data-based Mendelian randomization, and the heterogeneity in an independent instrument test, providing the most convincing evidence. These protein-coding genes are primarily expressed in macrophages, smooth muscle cells, and mast cells within abdominal aortic aneurysm tissue. Several causal proteins are involved in pathways regulating lipid metabolism, immune responses, and extracellular matrix organization. Nine proteins have already been targeted for drug development in diabetes and other cardiovascular diseases, presenting opportunities for repurposing as AAA therapeutic targets.
This study identifies causal proteins for AAA, enhancing our understanding of its molecular cause and advancing the development of therapeutics.
蛋白质组是治疗靶点的关键来源。我们对整个蛋白质组进行了全面的孟德尔随机化分析,以确定腹主动脉瘤(AAA)的潜在蛋白质标志物和治疗靶点。
我们的研究使用了来自英国生物银行的血浆蛋白质组学数据,包括54219名个体的2923种蛋白质,以及来自deCODE遗传学公司的数据,该公司对35559名个体的4907种蛋白质进行了测量。显著的蛋白质组学数量性状位点被用作孟德尔随机化的工具。与AAA的遗传关联来自AAAgen联盟(一项涉及37214例病例和1086107例对照的大规模全基因组关联研究荟萃分析)以及芬兰基因组研究(包括3869例病例和381977例对照)。进行了共定位和基于汇总数据的孟德尔随机化的序贯分析,以验证候选蛋白质的因果作用。此外,还进行了单细胞表达分析、蛋白质-蛋白质相互作用网络分析、通路富集分析和药物可及性评估,以确定表达富集的细胞类型并对潜在治疗靶点进行优先排序。全蛋白质组孟德尔随机化分析确定了34种与AAA风险相关的蛋白质。其中,COL6A3和PRKD2这两种蛋白质通过共定位分析、基于汇总数据的孟德尔随机化以及独立工具测试中的异质性得到突出显示,提供了最有说服力的证据。这些蛋白质编码基因主要在腹主动脉瘤组织内的巨噬细胞、平滑肌细胞和肥大细胞中表达。几种因果蛋白参与调节脂质代谢、免疫反应和细胞外基质组织的通路。已有9种蛋白质成为糖尿病和其他心血管疾病药物开发的靶点,为作为AAA治疗靶点重新利用提供了机会。
本研究确定了AAA的因果蛋白,加深了我们对其分子病因的理解,并推动了治疗方法的开发。